Biomed Industries to Present Research Findings on NA-831, Neurogenesis at Clinical Trials on Alzheimer's 2026 in Boston

Biomed Industries, Inc. and BiomedAI, Inc. to Present 4 Research Papers on NA-831, Neurogenesis and the Unified Theory at CTAD Conference 2026 in Boston

SAN JOSE, CA, UNITED STATES, November 10, 2026 /EINPresswire.com/ -- — Biomed Industries, Inc. and its subsidiary, BiomedAI, Inc., today announced four research poster presentations at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) International Conference, taking place November 16–19, 2026, in Boston, Massachusetts.

The research will be presented by Dr. Lloyd L. Tran, Chief Executive Officer, and Dr. Zung V. Tran, Vice President of Research and AI. The presentations bring together clinical investigation of NA-831, an investigational oral therapeutic candidate for Alzheimer’s disease, and AI-enabled approaches to understanding disease mechanisms and identifying potential treatments.
“Our four CTAD presentations reflect a common scientific goal: understanding how neuronal repair, metabolism, and vascular health influence Alzheimer’s disease,” said Dr. Lloyd L. Tran. “The Phase 2 findings for NA-831 provide evidence of safety and efficacy, supporting Phase 3 trials and further study of the neurogenesis hypothesis—a new frontier in Alzheimer’s research.."

PRESENTATION HIGHLIGHTS
P-128 — AI-Enabled Analysis of Anti-Aβ Clinical Trial Outcomes Supports Investigation of the Neurogenesis-Based Therapeutic Candidate NA-831 for Alzheimer’s Disease

This presentation analyzes published anti-amyloid antibody trial outcomes using bootstrap statistical methods and reports modest aggregate treatment effects across the studies examined. It also discusses separate Phase 2 findings for NA-831 and the application of AI and human real-world evidence to therapeutic development. The analysis supports investigation of complementary treatment mechanisms and does not establish comparative efficacy between NA-831 and anti-amyloid therapies.

P-127 — Artificial Intelligence–Guided Drug Repurposing for Alzheimer’s Disease Based on the Unified Theory of Neurodegenerative, Metabolic, and Cardiovascular Diseases

BiomedAI integrated molecular, pharmacological, and clinical datasets to identify existing medicines that may influence pathways shared by Alzheimer’s disease and metabolic and cardiovascular disorders. Three repurposing candidates—NA-850, NA-860, and NA-870—were prioritized based on predicted effects on mitochondrial function, inflammation, insulin signaling, and vascular health.

P-173 — Neurogenesis Hypothesis: Evidence from Phase 2 Clinical Trials of NA-831 for the Treatment of Alzheimer’s Disease

This presentation examines whether impaired hippocampal neurogenesis contributes to cognitive decline. A 24-week, randomized, placebo-controlled Phase 2 study enrolled 112 participants with mild cognitive impairment or Alzheimer’s disease dementia. The abstract reports a 4.1-point ADAS-Cog-13 benefit relative to placebo (p=0.001), with generally favorable tolerability. These findings support further clinical evaluation; the proposed neurogenesis mechanism requires additional validation.

P-174 — Unified Theory of Neurodegenerative, Metabolic and Cardiovascular Diseases: Clinical Evidence from NA-831 for Alzheimer’s Disease, NA-931 for Obesity, and NA-911 for Ischemic Stroke

This presentation reviews the Unified Theory of Neurodegenerative, Metabolic and Cardiovascular Diseases, proposed by Dr. Lloyd Tran to highlight clinical and translational findings from three investigational programs within a framework linking inflammation, mitochondrial dysfunction, insulin resistance, vascular injury, and impaired cellular regeneration. The research explores how targeting these shared processes could inform therapeutic development across neurological, metabolic, and cardiovascular diseases.
“Artificial intelligence helps us connect evidence across biological pathways, existing medicines, and clinical outcomes,” said Dr. Zung V. Tran. “Our goal is to translate these insights into better candidate selection and clinical trial design, with potential benefits established through rigorous clinical testing.”

ABOUT BIOMED INDUSTRIES, INC.
Biomed Industries, Inc. is a biopharmaceutical company developing investigational therapies for neurological, metabolic, and rare diseases. Its pipeline includes NA-831 for Alzheimer’s disease, NA-921 for Rett syndrome, NA-931 for obesity, and NA-911 for stroke. For more information, visit www.biomedind.com.

ABOUT BIOMEDAI, INC.
BiomedAI, Inc., a subsidiary of Biomed Industries, applies artificial intelligence to drug discovery, drug repurposing, and predictive medicine. Its research integrates computational analysis with biological and clinical evidence to guide therapeutic development. For more information, visit www.biomedai.com.

Forward-Looking Statements
This release contains forward-looking statements concerning research programs, therapeutic potential, and development plans. Actual results may differ materially because of scientific, clinical, regulatory, and other uncertainties. The therapeutic candidates discussed are investigational for the indications described.

David Lee
Biomed Industries, Inc.
+1 800-824-5135
Visit us on social media:
LinkedIn
X

Biomed introduction video